Tibor Kempf

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/910115/publications.pdf Version: 2024-02-01



TIROD KEMDE

#	Article	IF	CITATIONS
1	The Transforming Growth Factor-Î ² Superfamily Member Growth-Differentiation Factor-15 Protects the Heart From Ischemia/Reperfusion Injury. Circulation Research, 2006, 98, 351-360.	4.5	551
2	Prognostic Utility of Novel Biomarkers of Cardiovascular Stress. Circulation, 2012, 126, 1596-1604.	1.6	414
3	GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nature Medicine, 2011, 17, 581-588.	30.7	411
4	Prognostic Utility of Growth Differentiation Factor-15 in Patients With Chronic Heart Failure. Journal of the American College of Cardiology, 2007, 50, 1054-1060.	2.8	397
5	Growth Differentiation Factor 15 as a Biomarker in Cardiovascular Disease. Clinical Chemistry, 2017, 63, 140-151.	3.2	380
6	Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. Journal of Molecular and Cellular Cardiology, 2011, 51, 872-875.	1.9	350
7	Prognostic Value of Growth-Differentiation Factor-15 in Patients With Non–ST-Elevation Acute Coronary Syndrome. Circulation, 2007, 115, 962-971.	1.6	327
8	Serial Measurement of Growth-Differentiation Factor-15 in Heart Failure. Circulation, 2010, 122, 1387-1395.	1.6	272
9	Circulating Concentrations of Growth-Differentiation Factor 15 in Apparently Healthy Elderly Individuals and Patients with Chronic Heart Failure as Assessed by a New Immunoradiometric Sandwich Assay. Clinical Chemistry, 2007, 53, 284-291.	3.2	245
10	Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension. American Heart Journal, 2007, 153, 127-132.	2.7	243
11	Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study. European Heart Journal, 2009, 30, 2346-2353.	2.2	206
12	Growth Differentiation Factor 15 for Risk Stratification and Selection of an Invasive Treatment Strategy in Non–ST-Elevation Acute Coronary Syndrome. Circulation, 2007, 116, 1540-1548.	1.6	203
13	Transsignaling of Interleukin-6 Crucially Contributes to Atherosclerosis in Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 281-290.	2.4	203
14	Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction. European Heart Journal, 2007, 28, 2858-2865.	2.2	193
15	Bone marrow cells are a rich source of growth factors and cytokines: implications for cell therapy trials after myocardial infarction. European Heart Journal, 2008, 29, 2851-2858.	2.2	191
16	Myeloid-derived growth factor (C19orf10) mediates cardiac repair following myocardial infarction. Nature Medicine, 2015, 21, 140-149.	30.7	168
17	Growth Differentiation Factor-15 for Prognostic Assessment of Patients with Acute Pulmonary Embolism. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 1018-1025.	5.6	158
18	Attenuation of cardiac remodeling after myocardial infarction by muscle LIM protein-calcineurin signaling at the sarcomeric Z-disc. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 1655-1660.	7.1	143

#	Article	IF	CITATIONS
19	Growth Differentiation Factor-15 and Risk of Recurrent Events in Patients Stabilized After Acute Coronary Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 203-210.	2.4	138
20	Growth Differentiation Factor-15 in Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 534-541.	5.6	134
21	Growth differentiation factor 15 predicts future insulin resistance and impaired glucose control in obese nondiabetic individuals: results from the XENDOS trial. European Journal of Endocrinology, 2012, 167, 671-678.	3.7	134
22	Deficiency of liver sinusoidal scavenger receptors stabilin-1 and -2 in mice causes glomerulofibrotic nephropathy via impaired hepatic clearance of noxious blood factors. Journal of Clinical Investigation, 2011, 121, 703-714.	8.2	133
23	Iron-regulatory proteins secure iron availability in cardiomyocytes to prevent heart failure. European Heart Journal, 2016, 38, ehw333.	2.2	115
24	Growth-Differentiation Factor-15 for Risk Stratification in Patients With Stable and Unstable Coronary Heart Disease. Circulation: Cardiovascular Genetics, 2009, 2, 286-292.	5.1	113
25	Clinical and Genetic Correlates of Growth Differentiation Factor 15 in the Community. Clinical Chemistry, 2012, 58, 1582-1591.	3.2	106
26	Early albumin infusion improves global and local hemodynamics and reduces inflammatory response in hemorrhagic shock. Critical Care Medicine, 2002, 30, 851-855.	0.9	100
27	Multiple marker approach to risk stratification in patients with stable coronary artery disease. European Heart Journal, 2010, 31, 3024-3031.	2.2	97
28	Change in Growth Differentiation Factor 15 Concentrations over Time Independently Predicts Mortality in Community-Dwelling Elderly Individuals. Clinical Chemistry, 2013, 59, 1091-1098.	3.2	96
29	Growth Differentiation Factor 15 in Heart Failure: An Update. Current Heart Failure Reports, 2012, 9, 337-345.	3.3	95
30	Biomarkers of Cardiovascular Stress and Incident Chronic Kidney Disease. Clinical Chemistry, 2013, 59, 1613-1620.	3.2	91
31	Adjustment of the GRACE score by growth differentiation factor 15 enables a more accurate appreciation of risk in non-ST-elevation acute coronary syndrome. European Heart Journal, 2012, 33, 1095-1104.	2.2	88
32	Growth-Differentiation Factor-15 for Long-Term Risk Prediction in Patients Stabilized After an Episode of Non–ST-Segment–Elevation Acute Coronary Syndrome. Circulation: Cardiovascular Genetics, 2010, 3, 88-96.	5.1	82
33	GDF-15 is abundantly expressed in plexiform lesions in patients with pulmonary arterial hypertension and affects proliferation and apoptosis of pulmonary endothelial cells. Respiratory Research, 2011, 12, 62.	3.6	80
34	A simple non-invasive diagnostic algorithm for ruling out chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolism. Thrombosis Research, 2011, 128, 21-26.	1.7	76
35	Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer. Gynecologic Oncology, 2010, 118, 237-243.	1.4	74
36	Alterations of systemic and muscle iron metabolism in human subjects treated with low-dose recombinant erythropoietin. Blood, 2009, 113, 6707-6715.	1.4	70

#	Article	IF	CITATIONS
37	Downregulation of Cytoskeletal Muscle LIM Protein by Nitric Oxide. Circulation, 2003, 107, 1424-1432.	1.6	69
38	Early invasive versus non-invasive treatment in patients with non-ST-elevation acute coronary syndrome (FRISC-II): 15 year follow-up of a prospective, randomised, multicentre study. Lancet, The, 2016, 388, 1903-1911.	13.7	68
39	Growth-differentiation factor-15 for early risk stratification in patients with acute chest pain. European Heart Journal, 2008, 29, 2327-2335.	2.2	66
40	Growth-Differentiation Factor-15 in Heart Failure. Heart Failure Clinics, 2009, 5, 537-547.	2.1	64
41	Circulating Concentrations of Follistatin-Like 1 in Healthy Individuals and Patients with Acute Coronary Syndrome as Assessed by an Immunoluminometric Sandwich Assay. Clinical Chemistry, 2009, 55, 1794-1800.	3.2	63
42	Elevated Plasma Growth Differentiation Factor-15 Correlates with Lymph Node Metastases and Poor Survival in Endometrial Cancer. Clinical Cancer Research, 2011, 17, 4825-4833.	7.0	61
43	Conditional Transgenic Expression of Fibroblast Growth Factor 9 in the Adult Mouse Heart Reduces Heart Failure Mortality After Myocardial Infarction. Circulation, 2011, 123, 504-514.	1.6	60
44	Improving long-term risk prediction in patients with acute chest pain: The Global Registry of Acute Coronary Events (GRACE) risk score is enhanced by selected nonnecrosis biomarkers. American Heart Journal, 2010, 160, 88-94.	2.7	58
45	Anti-inflammatory mechanisms and therapeutic opportunities in myocardial infarct healing. Journal of Molecular Medicine, 2012, 90, 361-369.	3.9	57
46	Heme oxygenase-1 inhibition of MAP kinases, calcineurin/NFAT signaling, and hypertrophy in cardiac myocytes. Cardiovascular Research, 2004, 63, 545-552.	3.8	55
47	Circulating and Placental Growth-Differentiation Factor 15 in Preeclampsia and in Pregnancy Complicated by Diabetes Mellitus. Hypertension, 2009, 54, 106-112.	2.7	55
48	Incremental Prognostic Value of Biomarkers beyond the GRACE (Global Registry of Acute Coronary) Tj ETQq0 C Clinical Chemistry, 2013, 59, 1497-1505.) 0 rgBT /0\ 3.2	verlock 10 Tf 5 50
49	Biomarkers for characterization of heart failure – Distinction of heart failure with preserved and reduced ejection fraction. International Journal of Cardiology, 2017, 227, 272-277.	1.7	49
50	Leukocyte integrin activation and deactivation: novel mechanisms of balancing inflammation. Journal of Molecular Medicine, 2012, 90, 353-359.	3.9	48
51	Nitric oxide and the enigma of cardiac hypertrophy. BioEssays, 2004, 26, 608-615.	2.5	46
52	Identification of Follistatin-Like 1 by Expression Cloning as an Activator of the Growth Differentiation Factor 15 Gene and a Prognostic Biomarker in Acute Coronary Syndrome. Clinical Chemistry, 2012, 58, 1233-1241.	3.2	46
53	Growth Differentiation Factor-15: a New Biomarker in Cardiovascular Disease. Herz, 2009, 34, 594-599.	1.1	45
54	Risk scores and biomarkers for the prediction of 1-year outcome after transcatheter aortic valve replacement. American Heart Journal, 2015, 170, 821-829.	2.7	43

#	Article	IF	CITATIONS
55	Haeme oxygenase promotes progenitor cell mobilization, neovascularization, and functional recovery after critical hindlimb ischaemia in mice. Cardiovascular Research, 2008, 78, 294-300.	3.8	38
56	One-year outcomes with the HeartMate 3 left ventricular assist device. Journal of Thoracic and Cardiovascular Surgery, 2018, 156, 662-669.	0.8	38
57	Growth Differentiation Factor 15 Plasma Levels and Outcome after Ischemic Stroke. Cerebrovascular Diseases, 2011, 32, 72-78.	1.7	35
58	Relations of growth-differentiation factor-15 to biomarkers reflecting vascular pathologies in a population-based sample of elderly subjects. Scandinavian Journal of Clinical and Laboratory Investigation, 2012, 72, 45-51.	1.2	35
59	Growth-differentiation factor 15 for long-term prognostication in patients with non-ST-elevation acute coronary syndrome: An Invasive versus Conservative Treatment in Unstable coronary Syndromes (ICTUS) substudy. International Journal of Cardiology, 2014, 172, 356-363.	1.7	35
60	An Automated Assay for Growth Differentiation Factor 15. journal of applied laboratory medicine, The, 2017, 1, 510-521.	1.3	35
61	Cardiac iron concentration in relation to systemic iron status and disease severity in nonâ€ischaemic heart failure with reduced ejection fraction. European Journal of Heart Failure, 2020, 22, 2038-2046.	7.1	32
62	C1â€Esteraseâ€Inhibitor Treatment at Early Reperfusion of Hemorrhagic Shock Reduces Mesentery Leukocyte Adhesion and Rolling. Microcirculation, 2001, 8, 427-433.	1.8	30
63	Plastic Foil Technique Attenuates Inflammation in Mesenteric Intravital Microscopy. Journal of Surgical Research, 2000, 94, 28-34.	1.6	27
64	Biomarkers of Cardiovascular Stress and Subclinical Atherosclerosis in the Community. Clinical Chemistry, 2014, 60, 1402-1408.	3.2	24
65	Highly Specific Detection of Myostatin Prodomain by an Immunoradiometric Sandwich Assay in Serum of Healthy Individuals and Patients. PLoS ONE, 2013, 8, e80454.	2.5	24
66	Serum hepcidin levels and muscle iron proteins in humans injected with low―or highâ€dose erythropoietin. European Journal of Haematology, 2013, 91, 74-84.	2.2	23
67	Circulating concentrations of fibroblast activation protein \hat{I}_{\pm} in apparently healthy individuals and patients with acute coronary syndrome as assessed by sandwich ELISA. International Journal of Cardiology, 2013, 168, 3926-3931.	1.7	22
68	Oral iron supplementation with ferric maltol in patients with pulmonary hypertension. European Respiratory Journal, 2020, 56, 2000616.	6.7	22
69	Expression and clinical role of growth differentiation factor-15 in ovarian carcinoma effusions. International Journal of Gynecological Cancer, 2010, 20, 1448-55.	2.5	21
70	PLASMA PROTEIN LOSS DURING SURGERY: BENEFICIAL EFFECTS OF ALBUMIN SUBSTITUTION. Shock, 2001, 16, 9-14.	2.1	20
71	Evaluation of Temporal Changes in Cardiovascular Biomarker Concentrations Improves Risk Prediction in an Elderly Population from the Community. Clinical Chemistry, 2016, 62, 485-493.	3.2	17
72	GDFâ€15 in heart failure: providing insight into endâ€organ dysfunction and its recovery?. European Journal of Heart Failure, 2012, 14, 1191-1193.	7.1	13

#	Article	IF	CITATIONS
73	Plasma Concentrations of Myeloid-Derived Growth Factor in Healthy Individuals and Patients with Acute Myocardial Infarction as Assessed by Multiple Reaction Monitoring-Mass Spectrometry. Analytical Chemistry, 2019, 91, 1302-1308.	6.5	13
74	Intermediate CD14++CD16+ monocytes decline after transcatheter aortic valve replacement and correlate with functional capacity and left ventricular systolic function. PLoS ONE, 2017, 12, e0183670.	2.5	12
75	Risk stratification in critically ill patients: GDF-15 scores in adult respiratory distress syndrome. Critical Care, 2013, 17, 173.	5.8	11
76	Midregional proadrenomedullin and growth differentiation factor-15 are not influenced by obesity in heart failure patients. Clinical Research in Cardiology, 2017, 106, 401-410.	3.3	11
77	Iron and atherosclerosis: too much of a good thing can be bad. European Heart Journal, 2020, 41, 2696-2698.	2.2	7
78	Travelling with heart failure: risk assessment and practical recommendations. Nature Reviews Cardiology, 2022, 19, 302-313.	13.7	7
79	Mid-term results of interventional closure of patent foramen ovale with the Occlutech Figulla® Flex II Occluder. BMC Cardiovascular Disorders, 2016, 16, 217.	1.7	6
80	Iron supplementation in acute heart failure: energize your life. European Heart Journal, 2021, 42, 3021-3022.	2.2	6
81	Fulminant parvovirus B19 myocarditis after chemotherapy: full recovery after antiviral therapy with tenofovir. Clinical Research in Cardiology, 2022, 111, 233-236.	3.3	5
82	Anti-Inflammatory Treatment with Standardized Human Serum Protein Solution Reduces Local and Systemic Inflammatory Response after Hemorrhagic Shock. European Surgical Research, 2006, 38, 399-406.	1.3	3
83	Advanced Preconditioning: Impella 5.5 Support for Decompensated Heart Failure Before Left Ventricular Assist Device Surgery. Cardiovascular Revascularization Medicine, 2021, 28, 189-192.	0.8	3
84	Single coronary artery anomaly with interarterial left main: caught inbetween. European Heart Journal, 2015, 36, 762-762.	2.2	2
85	A mouse model of cardiogenic shock. Cardiovascular Research, 2021, 117, 2414-2415.	3.8	2
86	Novel selfâ€expanding <scp>ALLEGRA</scp> transcatheter aortic valve for native aortic stenosis and degenerated bioprosthesis. Catheterization and Cardiovascular Interventions, 2022, 99, 1234-1242.	1.7	2
87	Inter- and Intracellular Mechanisms of Cardiac Remodeling, Hypertrophy and Dysfunction. Cardiovascular Medicine, 2019, , 39-56.	0.0	1
88	Two vascular arteriovenous malformations with left-to-right shunting and right-heart failure in a single patient. International Journal of Cardiology, 2011, 149, e69-e71.	1.7	0